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ABSTRACT
Cytomegalovirus (CMV) infection is an important complication following allogeneic hematopoietic stem cell
transplant (HSCT), but the natural history in the cord blood setting has not been well studied. We assessed
CMV infection episodes in 753 consecutive allogeneic HSCT recipients at the University of Minnesota
between January 1, 1998 and December 31, 2003. The 6-month cumulative incidence of viremia/antigenemia
was 22% by day 182: 21% (95% confidence interval 16%-26%) in cord blood recipients (UCB), 24%
(20%-28%) in marrow (BM), and 22% (16%-28%) using peripheral blood grafts (PBSC). CMV disease
incidence was 6% (2%-10%) in UCB, 8% (5%-11%) in BM, and 9% (6%-12%) in PBSC. In multivariate
analysis, CMV infection (viremia/antigenemia and disease) was significantly more likely in patients who were
seropositive to CMV, in those with acute graft versus host disease, and in those receiving T cell-depleted
grafts. Graft source did not independently contribute to the risk of CMV infection and did not impact survival
after CMV infection. These data confirm that recipient CMV serostatus remains the dominant risk factor for
CMV infection. Recipients of UCB have similar risks of CMV infection, responses to antiviral therapy, and
survival following CMV infection as recipients of either marrow or PBSC.
© 2007 American Society for Blood and Marrow Transplantation
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oNTRODUCTION
Umbilical cord blood (UCB) is now a widely used
raft source for both adult as well as pediatric alloge-
eic hematopoietic stem cell transplantation (HSCT)
1-3]. Use of higher cell dosages, close histocompati-
ility leukocyte antigen (HLA) matches, and double
nit grafts have led to improved outcome [1].
Cytomegalovirus (CMV) viremia/antigenemia and
nd-organ disease affect HSCT recipients of all donor
ources [4]. Posttransplantation CMV infection is as-
ociated with recipient pretransplantation CMV
erostatus [5]. Because most CMV infections are re-
ctivations in seropositive recipients, CMV serologies
f cord blood donor infants and their mothers may not
mpact the risks of CMV infection in cord blood
ecipients [5,6]. The natural history of this important g
106iral infection in the cord blood setting is unclear
7-11], with infection rates ranging from 55% in a
ohort of 140 patients [11] to 100% in a group of 10
atients [8].
In the study of 10 patients where the incidence was
00%, there were 1 fatal case of pneumonitis and 2
ases of enteritis as end-organ manifestations of dis-
ase [8]. In another study, CMV antigenemia was seen
n 19 (79%) of 24 CMV-seropositive patients at a
edian of 42 days (range: 29-85 days) after cord blood
ransplant, but in zero of 4 CMV-seronegative pa-
ients [7]. In a study of 48 cord blood recipients, a 42%
ncidence of bloodstream reactivation compared
losely with a 38% incidence among contemporane-
us recipients of bone marrow and peripheral blood
raft sources [10].
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CMV in Cord Blood versus Marrow versus PBSC 1107To gain insight into the natural history of CMV
nfections following cord blood transplantation in a
arger cohort, we reviewed all cases of posttransplant
MV infection in 228 cord blood, 323 bone marrow
BM), and 202 peripheral blood stem cell (PBSC)
ransplant recipients. We evaluated demographic and
linical risk factors for CMV in each donor source
ype, including graft-versus-host disease (GVHD).
or those patients with established infection (viremia/
ntigenemia or end-organ disease), we examined clin-
cal outcomes in an attempt to deﬁne the antiviral
fﬁcacy of an 8-week course of antiviral therapy for
MV infections.
ATERIALS AND METHODS
tudy Patients and Setting
This retrospective cohort study included all con-
ecutive patients who received their ﬁrst allogeneic
SCT at the University of Minnesota between Janu-
ry 1, 1998 and December 31, 2003. Follow-up con-
inued for a minimum of 182 days. Study patients were
ensored after cancer relapse, graft failure, and at last
ollow-up. Patients received conditioning for trans-
lant and prophylaxis of GVHD per active institu-
ional protocols. All transplant protocols were ap-
roved by the University of Minnesota Institutional
eview Board. All patients or their legal guardians
rovided written consent for the transplantation pro-
edure.
The University of Minnesota HSCT database
ontains prospectively collected data on all patients
ransplanted at our center. Hospital charts and micro-
iology/virology records were examined for details of
ntiviral medications used to treat CMV infection
pisodes. Response to therapy was recorded at 12, 24,
6, and 48 weeks following onset of each infection
pisode. From the database we identiﬁed clinical data
ncluding age, gender, underlying diagnosis, type of
ransplant, donor source, conditioning regimen, re-
ipient and donor CMV serostatus, antiviral prophy-
axis, GVHD prophylaxis, transplantation complica-
ions, presence of GVHD, and survival.
iral Infection Prophylaxis
CMV-seropositive recipients or seronegative re-
ipients with seropositive donors received high dose
cyclovir prophylaxis [500 mg/m2 (10-12 mg/kg) in-
ravenously (i.v.) every 8 hours or 800 mg (18 mg/kg
ediatric) orally 5 times daily] until day 100 follow-
ng transplantation [12,13]. CMV-seronegative pa-
ients with a CMV-negative donor who were seropos-
tive for herpes simplex virus received low (half) dose
cyclovir prophylaxis daily until engraftment. All
lood products were leukoreduced by ﬁltration and
ntested for CMV status [14]. wDuring this study interval, a subset of 91 patients
ere randomly assigned, with stratiﬁcation for type of
ransplant, to either high dose oral acyclovir (n  46)
r intravenous maintenance ganciclovir (n 45), until
ay 100 following transplant [15]. Any degree of an-
igenemia was treated with ganciclovir.
MV Surveillance Monitoring
Antigenemia testing using the CMV-vue FITC kit
Diasorin Inc., Stillwater, MN) was performed weekly
fter day 14. Patients with a CMV-seronegative do-
or and recipient status were tested until day 60.
MV-seropositive recipients or patients with seropos-
tive donors were tested until day 100. Selected
atients continued with antigenemia testing after day
100, including patients at high risk for late CMV
patients treated with steroids for GVHD) or who had
eceived ganciclovir for CMV treatment prior to day
100. Low-grade antigenemia (1 positive cell/50,000)
as retested after 3 days. Antigenemia of 2 positive
ells per 50,000 leukocytes (or 1 positive cell/50,000
or Fanconi anemia patients) was treated with systemic
ntiviral agents. If there was severe neutropenia and
he patient was considered at high risk for CMV,
olecular testing (quantitative CMV DNA) was used
o supplement antigenemia testing for detection of
iremia. Standard methods were used for isolation of
MV from blood, bronchoalveolar lavage ﬂuid, and
issue samples, as previously described [16].
MV Therapy
For antigenemia at 2 positive cells/50,000, gan-
iclovir induction therapy was started at 5 mg/kg i.v.
wice daily for 2 weeks. Intravenous immune globulin
i.v. IG) was given at 500 mg/kg weekly for 3 doses if
n IgG level was 400 mg/dL (normal laboratory
ange, 695 to 1200 mg/dL). Maintenance therapy with
anciclovir was given with 5 mg/kg/day on weekdays
5 days per week) for 6 additional weeks. If antigen-
mia persisted following 2 weeks of ganciclovir induc-
ion therapy, a third week of ganciclovir was contin-
ed at induction doses. Persistent antigenemia after 21
ays of ganciclovir therapy or recurrent antigenemia
t 2 positive cells/50,000 cells after a 9-week course
as treated with alternative agents, usually with fos-
arnet or cidofovir.
For patients with a pulmonary inﬁltrate and re-
overy of CMV from a pulmonary source, ganciclovir
nduction therapy (5 mg/kg i.v. twice daily) was given
or 3 weeks; i.v. IG was given at 500 mg/kg every other
ay for 10 doses. Maintenance therapy with ganciclo-
ir was given with 5 mg/kg/day for 5 days per week for
additional weeks.
Immunohistochemical stains were performed on
ll tissue samples that were obtained from body sites
here CMV is a potential pathogen. For patients with
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C.M. Walker et al.1108ecovery of CMV in a gastrointestinal specimen by vi-
ology or pathology, including immunohistochemical
tain in the absence of inclusion bodies, ganciclovir
nduction therapy was given for 3 weeks. i.v. IG was
iven at 500 mg/kg weekly for 3 doses for some
atients with low IgG levels and severe disease, as
imited studies had shown no difference in either re-
ponse rates or survival with the addition of i.v. IG to
ntiviral therapy [17]. Maintenance therapy with gan-
iclovir was given with 5 mg/kg/day for 5 days per
eek for 6 additional weeks.
In the setting of renal insufﬁciency, induction gan-
iclovir doses were reduced to 2.5 mg/kg i.v. every 12
ours at a creatinine clearance of 70 mL/min, and
urther reduced to 2.5 mg/kg daily at a creatinine
learance of 50 mL/min.
Use of antiviral agents active against CMV for
ther reasons (human herpesvirus type-6 infection,
emorrhagic cystitis, Epstein-Barr virus infection,
tc.), was not speciﬁcally reviewed for those patients
ho did not reactivate CMV.
nfection Episodes and Evaluation Intervals
During and after treatment of viremia/antigenemia
r end-organ disease, response to treatment was mon-
tored by clinicians and evaluated weekly using the
ntigenemia test. A CMV infection episode was con-
idered resolved if initially positive tests were negative
t 12 weeks following the initial positive test. After a
2-week interval, new or recurrent positive CMV test-
ng was counted as a second infectious event. Break-
hrough CMV antigenemia that occurred prior to
ompletion of the 12-week interval was considered
art of the ﬁrst infection. Death or incomplete fol-
ow-up testing was analyzed as treatment failure.
tatistical Analysis
The primary endpoint of CMV infection (viremia/
ntigenemia or end-organ disease) by 6 months and
he secondary endpoint of CMV disease were esti-
ated by cumulative incidence treating nonevent
eaths as a competing risk and censoring patients at
raft failure and relapse [18]. Additional episodes of
nfections were summarized descriptively. Survival
ollowing infection was estimated by the Kaplan-
eier method [19]. Univariate comparisons of CMV
iremia/antigenemia and end-organ disease and sur-
ival were completed by using the log-rank statistic. A
ox proportional hazards model was used to model
he effect of potential predictors of outcomes includ-
ng: year of transplant, diagnosis, donor type and HLA
atch, stem cell source, recipient and donor gender,
MV serostatus at transplant, conditioning regimen,
VHD prophylaxis, and time-dependent develop-
ent of acute GVHD. All factors were tested for the
roportional hazards assumption [20]. aResponse to treatment was evaluated by compar-
son of the proportions of patients with negative tests
t 12 weeks after infection. The chi-square test was
sed to complete the comparison.
Comparisons of patient and transplant factors
cross stem cell source were completed by the chi-
quare test for categoric factors and the Wilcoxon test
or continuous factors.
ESULTS
Over 6 years, 753 patients received a ﬁrst alloge-
eic transplant at the University of Minnesota.
ransplant recipient demographic characteristics
re shown in Table 1, based on donor graft source.
edian age was 23.9 years (range: 0.3-69.6 years).
edian follow-up among survivors was 2.6 years
range: 1.0-6.6 years).
ncidence and Time of Diagnosis of CMV
fter Transplant
Of the 163 case patients with a CMV infection by
ay 182, 153 patients had viremia/antigenemia
21% incidence, 95% CI 18%-24%) and 54 patients
ad end-organ disease (8% incidence, 95% CI 6%-
0%). During the study period, the incidence of CMV
iremia/antigenemia remained constant at 20%-25%
f all patients each year.
The 6-month cumulative incidence of CMV vire-
ia/antigenemia was 21% (16%-26%) in cord blood
ecipients, 24% (20%-28%) in marrow, and 22%
16%-28%) using peripheral blood grafts. CMV end-
rgan disease incidence was 6% (2%-10%) in cord
lood, 8% (5%-11%) in marrow, and 9% (6%-12%)
n peripheral blood. These infection rates were similar
n all transplantation groups (Figure 1, P  .61).
The time to CMV infection following transplant
ppeared unimodal (the frequency curve was charac-
erized by 1 peak, histogram not shown). The onset of
ntigenemia occurred prior to day 100 for most
atients (145/163, 89%). The median initial positive
iagnostic test was day 43 (range, day 1  day
150). The cumulative incidence of CMV antigen-
mia was 22% by day 182 (95% CI, 19% to 25%).
here was similar onset in cord blood recipients (me-
ian onset day 33 [interquartile range: 25 to 41],
ersus day 35 [26 to 45] in marrow and day 50 [40
o 64] in peripheral blood).
A minority of patients were coinfected with CMV
nd aspergillosis. Among 26 such cases, 10 (6%) de-
eloped CMV infection following or within 14 days of
he fungal infection (median, 22 days; range: 14 to
7 days later). Most (86%) CMV infections were not
ssociated with an aspergillosis coinfection.
TO
A
R
Y
D
D
D
D
C
C
G
A
Y
M
N
F
CMV in Cord Blood versus Marrow versus PBSC 1109able 1. Patient and Transplant Characteristics
Factor Marrow PBSC UCB Total (%) P
verall 323 (43%) 202 (27%) 228 (30%) 753 (100%)
ge at transplant
<18 191 (59%) 11 (5%) 126 (55%) 328 (44%) <.01
>18 132 (41%) 191 (95%) 102 (45%) 425 (56%)
<20 202 (63%) 12 (6%) 132 (58%) 346 (46%) <.01
20-39 68 (21%) 62 (31%) 31 (14%) 161 (21%)
40 53 (16%) 128 (63%) 65 (29%) 246 (33%)
Median (range) 13 (0.3-58) 44 (0.9-69) 14 (0.3-64) 23 (0.3-69) <.01
ecipient/donor gender .24
Male/female 84 (26%) 61 (30%) 74 (32%) 219 (29%)
All others 239 (74%) 141 (70%) 154 (68%) 534 (71%)
ear of transplant <.01
1998-1999 156 (48%) 57 (28%) 32 (14%) 245 (33%)
2000-2001 116 (36%) 70 (35%) 77 (34%) 263 (35%)
2002-2003 51 (16%) 75 (37%) 119 (52%) 245 (33%)
iagnosis <.01
Nonmalignancy 140 (43%) 4 (2%) 61 (27%) 205 (27%)
Leukemias 170 (53%) 114 (56%) 142 (62%) 426 (57%)
Other malignancies 13 (4%) 84 (42%) 25 (11%) 122 (16%)
iagnosis category <.01
Nonmalignant 140 (43%) 4 (2%) 61 (27%) 205 (27%)
Acute leukemia/MDS 104 (32%) 91 (45%) 122 (54%) 317 (42%)
CML 51 (16%) 14 (7%) 11 (5%) 76 (10%)
NHL/HD 9 (3%) 60 (30%) 19 (8%) 88 (12%)
Other malignancy 19 (6%) 33 (16%) 15 (7%) 67 (9%)
onor type and HLA <.01
RD HLA match 116 (36%) 181 (90%) 6 (3%) 303 (40%)
RD HLA mm/URD HLA mm 62 (19%) 20 (10%) 204 (89%) 286 (38%)
URD HLA match 145 (45%) 1 (1%) 18 (8%) 164 (22%)
onor type <.01
RD 134 (41%) 200 (99%) 0 334 (44%)
URD 189 (59%) 2 (1%) 0 191 (25%)
Cord blood 0 0 228 (100%) 228 (30%)
MV serology <.01
R/D 131 (41%) 70 (35%) 125 (55%) 326 (43%)
R/D 61 (19%) 33 (16%) 0 94 (12%)
R/D 73 (23%) 40 (20%) 103 (45%) 216 (29%)
R/D 58 (18%) 59 (29%) 0 117 (16%)
onditioning regimen <.01
Myeloablative 304 (94%) 152 (75%) 164 (72%) 620 (82%)
Nonmyeloablative 19 (6%) 50 (25%) 64 (28%) 133 (18%)
VHD prophylaxis <.01
Methotrexate/CsA 167 (52%) 150 (74%) 0 317 (42%)
T deplete 92 (28%) 0 0 92 (12%)
CsA/Prednisone  ATG 43 (13%) 0 0 43 (6%)
CsA  MMF 21 (7%) 52 (26%) 228 (100%) 301 (40%)
ntiviral prophylaxis <.01
None 192 (59%) 104 (51%) 125 (55%) 421 (56%)
Acyclovir 120 (37%) 95 (47%) 103 (45%) 318 (42%)
Acyclovir  Ganciclovir [15] 11 (3%) 3 (2%) 0 14 (2%)
ears of follow-up among survivors
Median (range) 3.6 (1-6.3) 2.1 (1-5.7) 2.0 (1-6.6) 2.6 (1.0-6.6) <.01
arrow indicates bone marrow transplant; PSBCT, peripheral blood stem cell transplant; UCB, umbilical cord blood transplant; MDS,
myelodysplastic syndrome; CML, chronic myelogenous leukemia; NHL, non-Hodgkin’s lymphoma; HD, Hodgkin’s disease; HLA, human
leukocyte antigen; RD, related donor; URD, unrelated donor; mm, mismatch; CMV, cytomegalovirus; R, recipient; D, donor; GVHD,
graft-versus-host disease; CsA, cyclosporine; ATG, antithymocyte globulin; MMF, mycophenolate mofetil.
onmalignancy includes aplastic anemia, immune deﬁciency, hemoglobinopathy, and storage disorders. Leukemias include acute lymphocytic
leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, other malignancy/leukemia, and myelodysplastic syndrome. Other
malignancies include non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, neuroblastoma, and breast cancer.
or donor matching, all matches were 6/6 and all mismatches were 6/6. Related donors were matched to the antigen level (A, B, DR), and
unrelated donors including cord units were matched using high resolution typing (A, B, DRB).
Ri
g
e

w
a
b
C
l
t
d
P
c
1
a
p
u
i
0
9
S

T
d
c
a
e
t
w
a
1
r
t
s
t
c
3
w
F
w
T
O
R
A
C
A
G
C
C.M. Walker et al.1110isk Factors for CMV Infection following HSCT
The univariate and adjusted risk factors for CMV
nfection are presented in Tables 2 and 3. Neither
ender nor gender match between donor and recipi-
nt had an impact on the risk of CMV infection. Age
18 years and use of speciﬁc antiviral prophylaxis
ere risk factors in the univariate but not multivariate
nalysis. However, antiviral prophylaxis is confounded
y assignment based on CMV serostatus.
In the Cox multivariate regression analysis (Table 3),
MV seropositive recipients were signiﬁcantly more
ikely to develop CMV infection than were seronega-
ive patients with either a CMV positive or negative
onor (relative risk [RR] 11.8 and 14.5) (P  .01).
igure 1. The 6-month cumulative incidence of CMV infection
as 22%.
able 2. Univariate Analysis of Risk Factors for Cytomegalovirus Infec
Factor N # Events
verall 753 163
ecipient/donor gender
Male/female 219 40
All others 534 123
ge (years)
<18 328 60
>18 425 103
0-19 346 67
20-39 161 42
40 246 54
MV serology
R/D 326 14
R/D 94 8
R/D 216 97
R/D 117 44
ntiviral prophylaxis
None 421 22
Acyclovir 318 135
Acyclovir  Ganciclovir [15] 14 6
raft source 323 75
Marrow 202 41
PBSC 228 47
Cord blood
MV indicates cytomegalovirus; R, recipient; D, donor; PSBC, per
cumulative incidence (95% conﬁdence interval) and competing non-Catients receiving T cell-depleted grafts were at in-
reased risk of CMV infection (RR 2.2; 95% CI,
.5-3.4). Patients who developed acute GVHD were
lso at increased risk (RR 2.6; 95% CI, 1.9-3.6). Im-
ortantly, graft source did not independently contrib-
te to the risk of CMV infection as risks were similar
n recipients of bone marrow versus cord blood (RR
.8; 95% CI, 0.5-1.3) versus peripheral blood (RR 0.6;
5% CI, 0.4-1.0).
ites of CMV Infection
Of 163 patients developing CMV infection by day
182, 54 patients had 59 sites of end-organ disease.
hirty-nine patients developed CMV pneumonitis, 17
eveloped gastrointestinal disease, and 3 developed
entral nervous system disease (3 had both respiratory
nd gastrointestinal infection, and 1 patient had dis-
ase disseminated to all 3 of these sites).
The sites of end-organ disease were not different for
he 3 stem cell sources. For marrow recipients, there
ere 18 lung infections, 10 gastrointestinal infections,
nd 2 central nervous system infections; this includes
recipient with gastrointestinal plus lung sites. For pe-
ipheral blood graft recipients, there were 11 lung infec-
ions, 4 gastrointestinal infections, and 1 central nervous
ystem infection; this includes 1 recipient with gastroin-
estinal plus lung sites and 1 recipient with all 3 sites. For
ord blood recipients, there were 10 lung infections and
gastrointestinal infections; this includes 1 recipient
ith gastrointestinal plus lung sites.
Day 182 CMV
Incidence (95% CI)
Day 182 Non-CMV
Mortality (95% CI) P
22% (19-25%) 16% (14-18%)
.14
19% (14-24%) 16% (11-21%)
24% (21-27%) 16% (13-19%)
.02
18% (14-22%) 12% (9-15%)
25% (21-29%) 20% (16-24%)
20% (16-24%) 12% (9-15%) .14
27% (20-34%) 16% (9-21%)
23% (18-28%) 22% (17-27%)
<.01
4% (2-6%) 18% (14-22%)
9% (3-15%) 17% (9-25%)
47% (40-54%) 15% (10-20%)
38% (29-47%) 13% (7-19%)
<.01
5% (3-7%) 18% (14-22%)
44% (38-50%) 14% (10-18%)
43% (17-69%) 14% (0-31%)
24% (19-29%) 14% (10-18%) .69
22% (16-28%) 18% (13-23%)
21% (16-26%) 17% (12-22%)
blood stem cell transplant; CI, conﬁdence interval. Shown are thetion
ipheral
MV mortality incidence before day 182 following HSCT.
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CMV in Cord Blood versus Marrow versus PBSC 1111Most (43 of 54, 80%) patients had antigenemia
receding CMV end-organ disease. Among the 80%
f patients with antigenemia and end-organ disease,
nly 1 patient ﬁrst developed antigenemia after the
nset of end-organ disease (Table 4).
linical Response to Antiviral Treatment
Initial treatment courses for 163 case patients in-
luded ganciclovir (n  152, 93%), foscarnet (n  6),
alganciclovir (n  2), and other therapy (n  3).
esponse rates to initial ganciclovir courses were sim-
lar in recipients of UCB (28/44 responded, 63.6%),
M (48/69 responded, 69.6%), and PBSC (28/39 re-
ponded, 70.0%). No clinical factors predicted re-
ponse to therapy including age, CMV serostatus, or
ctive GVHD.
One hundred four (68.5%) had a complete re-
ponse to ganciclovir within 12 weeks, while 22
14.5%) died prior to the 12 week evaluation point.
wenty-six (17%) did not respond to ganciclovir. Five
ho did not respond within 12 weeks were maintained
n ganciclovir for a longer period of time: 3 (60%)
esponded; 1 patient with long standing end-organ
isease of the central nervous system did not respond.
eventeen nonresponders were switched to foscarnet
able 3. Multivariate Analysis of Risk Factors for Cytomegalovirus
nfection
Factor RR (95% CI) P
MV serology
R/D 1.0
R/D 1.9 (0.8-4.6) .14
R/D 14.5 (8.3-25.5) <.01
R/D 12.0 (6.5-22.4) <.01
VHD prophylaxis
No T cell depletion 1.0
T depletion 2.2 (1.2-3.2) <.01
cute GVHD (time dependent)
No 1.0
Yes 2.5 (1.8-3.5) <.01
raft source
Marrow 1.0
UCB 0.8 (0.5-1.3) .44
PBSC 0.6 (0.4-1.0) .06
ge
<18 years 1.0
>18 years 1.4 (1.0-2.0) .05
arrow indicates bone marrow transplant; PSBCT, peripheral
blood stem cell transplant; UCB, umbilical cord blood trans-
plant; CMV, cytomegalovirus; R, recipient; D, donor; GVHD,
graft-versus-host disease; RR, relative risk; CI, conﬁdence
interval.
ll factors tested for proportional hazards. Factors that were in-
cluded in initial model were age, donor type, patient and donor
gender, patient and donor cytomegalovirus serostatus, season of
transplant, acute GVHD, GVHD prophylaxis, conditioning,
stem cell source, HLA disparity, and underlying diagnosis.nd 6 (35%) responded. There were 4 ganciclovironresponders who were treated with cidofovir:
responded; 1 later responded to foscarnet.
Six patients were treated initially with foscarnet,
sually due to leukopenia at onset of infection. One
atient (17%) responded to foscarnet within 12 weeks.
f the 5 nonresponders, 4 were switched to ganciclo-
ir, and 1 (20%) responded to ganciclovir. One other
as switched back to foscarnet and responded with
learing of the infection. One was changed to cidofo-
ir, then switched to ganciclovir, and later died.
Two patients were treated initially with valganci-
lovir, and 1 patient responded within 12 weeks.
dditional Infections
There were 29 second CMV infection episodes
ollowing a successful ﬁrst treatment course, with no
ifferences in the frequency of CMV recurrence
mong the 3 graft sources. For UCB, 6 of the total 47
ecipients had second infections or approximately
2.8%, for BM (15/75 or 20%), and PBSC (8/41 or
9.5%).
Treatment courses for these 29 cases included
anciclovir (n  20), foscarnet (n  6), valganciclovir
n  2), and none (n  1). Of the patients who had
reviously responded to ganciclovir and were again
reated with ganciclovir, 12 (63%) of the patients
gain responded to therapy at 12 weeks, 2 responded
ithin 24 weeks, and 3 nonresponders to ganciclovir
t 12 weeks’ time were switched to foscarnet and
esponded within 24 weeks. One patient who had
ailed ganciclovir for the ﬁrst infection responded to
anciclovir therapy in their second infection episode.
ix were treated with foscarnet for the recurrent in-
ection: 2 responded to foscarnet, 2 died, 1 failed
oscarnet was retreated with ganciclovir and re-
ponded. The 2 patients treated with valganciclovir
or recurrent infection both responded.
urvival of Patients with CMV Infection
Among the 163 patients, there were 87 deaths.
MV was implicated in 20% of these deaths as a
ontributing cause of death. Six-month survival after
ntigenemia was 67% (60%-74%) and was superior to
able 4. Cytomegalovirus End-Organ Disease Site by Antigenemia
tatus
Antigenemia Status
Site
No
Antigenemia
Positive
Antigenemia Total
espiratory 7 28 35
astrointestinal 3 10 13
ervous system 1 1 2
ultiorgan involvement 0 4 4
otal 11 (20%) 43 (80%) 54
ne patient had ﬁrst positive antigen following the diagnosis of
cytomegalovirus enteritis.
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C.M. Walker et al.1112urvival after end-organ infection (43% [30%-56%]).
he 1-year survival rate after CMV infection was 55%
95% CI, 47%-62%), whereas the 1-year survival of
atients that did not have CMV infection was 62%
95% CI, 58%-66%) (Figure 2). The 5-year survival
fter CMV infection was 40% (range: 31%-49%,
able 5).
For patients 18 years of age, 1-year and 5-year
urvival rates were 60% and 48%, respectively, com-
ared with 52% and 36% among patients older than
8 years old (P  .15). One-year survival following
MV infection was similar in recipients of UCB
58%), BM (59%), or PBSC (46%) (P  .35). Neither
ender, CMV serology, underlying disease, nor CMV
rophylaxis showed a signiﬁcant impact on survival.
ISCUSSION
This analysis allowed direct comparison of the im-
ortance of graft source on the incidence and response to
herapy of CMV infection after HSCT. Recipients of
CB grafts had similar incidence and outcome of CMV
nfection as did recipients of HSCT from either BM or
BSC sources. Although the proportion of patients get-
ing infection was not different, there was a slight delay
n infection among PBSC when compared to UCB and
M. Importantly, despite improved early detection and
herapy in transplant recipients of all donor sources,
igure 2. a, The 1-year survival rate after CMV infection was 55%.
, The 1-year survival of patients that did not have CMV infection
as 62%.MV infection remains an important burden, as 22% of whe patients had evidence of CMV viremia within the
rst 6 months of HSCT.
Among the 3 graft sources, there were no differ-
nces in response to the ﬁrst course of ganciclovir
herapy, no differences in the sites of CMV end-organ
isease, no differences in the frequency of recurrent
MV infection, and no differences in 1-year survival.
s a result, we have combined the descriptive passages
egarding end-organ disease and response to therapy
o provide more meaningful information.
Recipient CMV serostatus was the most important
isk factor that predicted the reactivation of CMV
nfection or disease in our study cohort, as previously
hown [21,22]. Among the 228 recipients of cord
lood, reactivation was completely predicted on recip-
ent serostatus, as no cases occurred in CMV seroneg-
tive cord blood recipients. All cord units were sero-
egative for CMV, because most babies are born
ithout CMV infection. CMV screening of the donor
air (infant and mother) has little to no impact on
eactivation of CMV infections [5,6]. Because CMV
urviellance monitoring was not started before day
14 following HSCT, early CMV reactivation may
ave been missed.
Ganciclovir is considered to be ﬁrst-line therapy
n the treatment of CMV infection among immuno-
ompromised patients. Ganciclovir is an effective pre-
mptive or prophylactic treatment in the HSCT set-
ing [23-31]. Due to its myelosuppressive effects and
ssociation with increased risk of bacterial infections
26,27,32], ganciclovir is most commonly used in pre-
mptive fashion to reduce the incidence of CMV dis-
ase with less toxicity [33,34]. Our study demonstrates
he effectiveness of ganciclovir when used for pre-
eﬁned 8-week treatment courses of CMV infection:
8.5% cure rate within 12 weeks of the onset of the
rst infection. Persisting CMV infection at 12 weeks
ay be treated with a longer course of ganciclovir.
ive (71%) patients who continued ganciclovir treat-
ent beyond 12 weeks eventually responded to the
edication.
Alternatively, foscarnet and cidofovir have been
hown to be effective therapy for CMV infection in
llogeneic HSCT recipients [35-39], but the potential
or nephrotoxicity has restricted their use in HSCT
ecipients.
In 1 study examining foscarnet to treat antigen-
mia among HSCT recipients, 17 of 20 patients re-
ponded to therapy [38]. In a case of graft failure
receding CMV infection, viremia was successfully
reated with a combination of foscarnet and leﬂuno-
ide [37]. In 10 cord blood recipients who were un-
ble to receive ganciclovir due to cytopenia or poor
esponse to ganciclovir, foscarnet was well tolerated,
ith resolution of antigenemia without progression to
isease in 90% [40]. When reduced-dose foscarnet
as used to treat recipients of reduced-intensity cord
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CMV in Cord Blood versus Marrow versus PBSC 1113lood transplantation with CMV antigenemia exceed-
ng 10 cells/50,000, 3 patients were diagnosed with
nterocolitis within 5, 14, and 17 days following in the
nitiation of foscarnet [41]. In our cohort, foscarnet
as used infrequently as an alternative to ganciclovir,
ither for primary infection that occurred during neu-
ropenia, and after an initial course of failed ganciclo-
ir therapy. Foscarnet response rates of 20% and 35%
ere observed.
A retrospective study showed successful responses
o cidofovir, including 10 of 20 (50%) who were
reated for CMV disease, 25 of 38 (66%) who had
able 5. Survival Following Cytomegalovirus Infection
Factor N # Deat
163 87*
ge (years)
<18 60 27
>18 103 60
ender
Male 89 49
Female 74 38
MV serology
R/D 14 7
R/D 8 3
R/D 98 47
R/D 44 30
nderlying disease
Nonmalignancy 49 24
Acute leukemia/MDS 61 37
CML 19 11
NHL/HD 19 8
Other malignancies 15 7
ntiviral prophylaxis
None 22 10
Acyclovir 128 71
Acyclovir  Acyclovir [15] 7 3
Acyclovir  Ganciclovir [15] 6 3
onor type
RD match 60 32
URD match 34 23
RD or URD mm 22 10
Cord blood 47 22
onor source
Marrow 76 40
PBSC 43 27
UCB 48 22
onditioning
Myeloablative 139 73
Nonmyeloablative 24 14
vHD prophylaxis
Methotrexate/Cyclosporine 67 36
T cell depletion 27 16
CsA/MMF 62 31
CsA/Prednisone 7 4
ays from transplant to CMV
Infection
<40 89 47
>40 74 40
E indicates not evaluable. Other abbreviations as in Table 1.
Twenty deaths (22%) with CMV listed as a contributing cause ofailed or relapsed after previous preemptive therapy,nd 15 of 24 (62%) patients in whom cidofovir was
sed as the primary preemptive therapy [36]. In an-
ther study, 5 of 8 allogeneic pediatric HSCT patients
ad complete response of antigenemia with cidofovir,
hile 3 were switched to foscarnet or ganciclovir [42].
e feel that cidofovir is a third-line alternative for
reatment of CMV infections. Due to its long half-life
nd renal toxicity, cidofovir was reserved for speciﬁc
linical scenarios such as viral resistance or concurrent
nfection with adenovirus or BK virus. In our study,
nly 5 patients were treated with cidofovir. All were
anciclovir failures, and only 1 patient responded.
1-Year Survival
(95% CI)
5-Year Survival
(95% CI) P
55% (47-62%) 40% (31-49%)
.15
60% (47-72%) 48% (32-64%)
52% (42-62%) 36% (25-47%)
.62
51% (41-62%) 39% (26-50%)
59% (48-71%) 40% (26-54%)
.27
63% (38-89%) 48% (21-75%)
75% (45-100%) 60% (24-96%)
57% (47-67%) 44% (31-58%)
45% (30-60%) 26% (11-41%)
.56
59% (45-73%) 44% (28-61%)
51% (38-63%) 30% (15-44%)
53% (30-75%) 41% (18-64%)
58% (36-80%) 58% (36-80%)
67% (43-91%) 52% (26-78%)
.53
68% (48-88%) 52% (30-74%)
52% (43-61%) 34% (22-46%)
57% (20-94%) NE
67% (29-100%) NE
.35
63% (51-75%) 32% (13-50%)
38% (22-54%) 32% (16-48%)
55% (34-75%) 55% (34-75%)
57% (43-71%) 46% (28-65%)
.27
59% (47-69%) 43% (30-55%)
46% (31-60%) 30% (14-47%)
58% (42-70%) 47% (27-64%)
.47
55% (47-63%) 41% (31-51%)
54% (34-74%) NE
.93
60% (48-71%) 41% (28-55%)
48% (29-67%) 38% (18-58%)
54% (42-67%) NE
38% (0-77%) NE
.79
56% (46-66%) 42% (29-54%)
54% (42-65%) 39% (25-52%)hsDetection of bloodstream reactivation is fast, sen-
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C.M. Walker et al.1114itive, and speciﬁc using weekly monitoring tests
24,26,43,44]. Progression to end-organ disease such
s interstitial pneumonitis is difﬁcult to treat once
stablished [45]. In this report, 1/5 of CMV end-organ
isease was not preceded by surveillance detection of
MV antigenemia. These results are similar to previ-
us studies which showed a 12%-32% incidence of
MV disease without viremia [25,27,46,47].
A limitation of this study is a lack of data regarding
MV surveillance monitoring of patients beyond day
100. Patients who are doing well will leave the
ransplant center and return to their home clinic at
his point. However, patients requiring monitoring
or GVHD and other complications may be followed
n transplant center beyond day 100 and receive
ontinued screening at their visits. These data, com-
ined with correspondence from outside physicians,
orm the basis for the day 182 endpoints of this
tudy.
We observed CMV reactivation in nearly 30% of
rst allogeneic HSCT recipients despite antiviral pro-
hylaxis and leukoreduced blood products. Impor-
antly, CMV risks were similar in UCB and other
raft source recipients, but CMV-seropositive recipi-
nt serostatus and moderate to severe GVHD remain
he most important risk factors for CMV infection.
anciclovir is the initial and generally effective anti-
iral treatment of choice for CMV infection and dis-
ase. Foscarnet remains the ﬁrst alternative to ganci-
lovir, either for patients with myelosuppression or for
anciclovir treatment failures. Finally, a negative
loodstream surveillance test for CMV does not pre-
lude serious CMV disease, especially in the leukope-
ic patient.
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